色情直播 青年研究员PI，博士生导师，入选上海“海外高层次人才引进计划”和“高校青年英才揽蓄工程”。博士毕业于新西兰奥塔哥大学色情直播 ，研究领域为群体药代动力学药效学和定量系统药理学，师从本领域著名专家Stephen Duffull教授。已主持国家自然科学基金等各类基金项目3项，荣获2019年度国家优秀自费留学生奖和2019年大洋洲临床和实验药理学家毒理学家学会Fred Fastier奖，曾在2019年欧洲定量药理学年会(PAGE)的Stuart Beal方法学专题做大会报告。近年来以第一作者/通讯作者在Adv. Sci., Br. J. Pharmacol.(4篇), J. Antimicrob. Chemother., Antimicrob. Agents Chemother.等国际权威期刊发表高水平科研论文20余篇，并参与多项CDE指导原则的编写。现为中国药理学会定量药理专委会委员，中国药理学会临床药理专委会青年委员，中国; ; ; ; ; ; ; ; *; Identifying a therapeutic target for vancomycin against staphylococci in young infants, The Journal of Antimicrobial Chemotherapy, 2022, 77(3): 704-710
10. #; #; *; ; ; Impact of Hospital Characteristics and Governance Structure on the Adoption of Tracking Technologies for Clinical and Supply Chain Use: Longitudinal Study of US Hospitals,Journal of Medical Internet Research,2022, 24(5): e33742
11. #; #; ; ; ; ; ; *; *; *; Model-Informed Drug Development of New Cefoperazone Sodium and Sulbactam Sodium Combination (3:1): Pharmacokinetic/Pharmacodynamic Analysis and Antibacterial Efficacy Against Enterobacteriaceae, Frontiers in Pharmacology, 2022, 13: 856792
12. *; ; ; ; Evaluation of the profiles of CB1 cannabinoid receptor signalling bias using joint kinetic modelling, British Journal of Pharmacology, 2020, 177(15): 3449-3463.
13. #; #; *; *; Model-free and kinetic modelling approaches for characterising non-equilibrium pharmacological pathway activity: Internalisation of cannabinoid CB1 receptors, British Journal of Pharmacology, 2019, 176(14): 2593-2607
14. *; ; ; ; An evaluation of the operational model when applied to quantify functional selectivity, British Journal of Pharmacology, 2018, 175(10): 1654-1668
15. ; ; ; ; ; ; *; ; ; Model-informed drug development of benapenem: Pharmacokinetic/Pharmacodynamic cutoff value determination and antibacterial efficacy against enterobacteriaceae, Antimicrobial Agents and Chemotherapy, 2020, 64(3): e01751-19
16. #; #; ; ; ; *; Mechanistic Pharmacokinetic/Pharmacodynamic Model of Sunitinib and Dopamine in MCF-7/Adr Xenografts: Linking Cellular Heterogeneity to Tumour Burden,The AAPS Journal, 2020, 22(2): 45
17. ; ; ; *; Understanding the association between metformin plasma concentrations and lactate, British Journal of Clinical Pharmacology, 2020,87(2): 700-701
18. ; ; ; ; ; *; Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID‐19, British Journal of Clinical Pharmacology, 2020, 87(3): 1589-1590
19. *; ; ; ; An intact model for quantifying functional selectivity, Scientific Reports, 2019, 9(1): 2557
20. ; ; ; *; An Agent-Based Approach to Dynamically Represent the Pharmacokinetic Properties of Baicalein, The AAPS Journal, 2016, 18(6): 1475-1488
21. Xi-Wei Ji; Xiang-Rui Meng; Qing-Feng He; Xiao-Qiang Xiang; Yufei Shi*; Xiao Zhu*; Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling, International Journal of Molecular Sciences, 2023, 24(1):757
22. Qiu-Yu Jia#; Qing-Feng He#; Li Yao; Min Li; Jia-Ying Lin; Zhi-Jia Tang; Xiao Zhu*; Xiao-Qiang Xiang*; Utilization of Physiologically Based Pharmacokinetic Modeling in Pharmacokinetic Study of Natural Medicine: An Overview, Molecules, 2022,27(24):8670
其他论文
1. Amanda L Wilkins; Tony Lai; Xiao Zhu; Srinivas Bolisetty; Roberto Chiletti; Noel Cranswick; Kaya Gardiner; Rodney Hunt; Atul Malhotra; Brendan McMullan; Bhavesh Mehta; Joanna Michalowski; Himanshu Popat; Meredith Ward; Stephen Duffull; Nigel Curtis; Amanda Gwee*; Individualized vancomycin dosing in infants: prospective evaluation of an online dose calculator, International Journal of Antimicrobial Agents, 2023, 61(3): 106728.
2. Xiaowen Wang; Yiqun Yu; Hongrui Liu; Fengjiao Bu; Chunying Shen; Qingfeng He; Xiao Zhu; Pin Jiang; Bing Han*; Xiaoqiang Xiang*; Prediction of Drug-Drug Interactions with Ensartinib as a Time-Dependent CYP3A Inhibitor Using Physiologically Based Pharmacokinetic Model. Drug Metab Dispos. 2023;51(11):1515-1526
3. Chunyang Pan; Yifan Cheng; Qingfeng He; Min Li; Fengjiao Bu; Xiao Zhu; Xiaoyu Li; Xiaoqiang Xiang*; Evaluating the impact of co-administered drug and disease on ripretinib exposure: A physiologically-based pharmacokinetic modeling approach, Chemico-Biological Interactions, 2023, 373: 110400.
4. Yawen Yuan; Zhihong Li; Ke Wang; Shunguo Zhang; Qingfeng He; Lucy Liu; Zhijia Tang; Xiao Zhu; Ying Chen; Weimin Cai; Chao Peng; Xiaoqiang Xiang*; Pharmacokinetics of Novel Furoxan/Coumarin Hybrids in Rats Using LC-MS/MS Method and Physiologically Based Pharmacokinetic Model, Molecules, 2023, 28(2): 837
5. Yawen Yuan; Changcheng Chen; Guoling You; Ruen Yao; Xiao Zhu; Xiaoyu Wu; Juan Wu; Wei Zhao; Zhiling Li; Shunguo Zhang*; Simultaneous quantification and pharmacokinetics of vincristine and its major metabolite M1 in Chinese pediatric ALL patients by LC-MS/MS, Journal of Pharmaceutical and Biomedical Analysis, 2023, 234: 115578
6. #; #*; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Timing of live attenuated vaccination in infants exposed to infliximab or adalimumab in utero: A prospective cohort study in 107 children, Journal of Crohn's & Colitis, 2022, 16(12): 1835-1844
7. Xiwei Ji#; Xiangrui Meng#; Xiao Zhu; Qingfeng He; Yimin Cui*; Research and development of Chinese anti-COVID-19 drugs, Acta Pharmaceutica Sinica. B, 2022
8. Qingfeng He#; Fengjiao Bu#; Qizhen Wang; Min Li; Jiaying Lin; Zhijia Tang; Wen Yao Mak; Xiaomei Zhuang; Xiao Zhu; Hai-shu Lin*; Xiaoqiang Xiang*; Examination of the Impact of CYP3A4/5 on Drug–Drug Interaction between Schizandrol A/Schizandrol B and Tacrolimus (FK-506): A Physiologically Based Pharmacokinetic Modeling Approach, International Journal of Molecular Sciences, 2022, 23(9): 4485
9. Yawen Yuan#; Qingfeng He#; Shunguo Zhang; Min Li; Zhijia Tang; Xiao Zhu; Zheng Jiao; Weimin Cai*; Xiaoqiang Xiang*; Application of Physiologically-based Pharmacokinetic Modeling in Preclinical Studies: A Feasible Strategy to Practice the Principles of 3Rs, Frontiers in Pharmacology, 2022, 13: 895556
10. Zhipin Jin#; Qingfeng He#; Xiao Zhu; Mingshe Zhu; Yike Wang; Xin-an Wu; Qianzhou Lv*; Xiaoqiang Xiang*; Application of physiologically based pharmacokinetic modelling for the prediction of drug–drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes, Basic & Clinical Pharmacology & Toxicology, 2022, 130(5): 592-605
11. Zhen Feng; Xiaoye Li; Wai Kei Tong; Qingfeng He; Xiao Zhu; Xiaoqiang Xiang; Zhijia Tang*; Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS,*; ; ; ; ; Exploring group size for statistical analysis of real-time signalling experiments, British Journal of Pharmacology, 2021, 178(19):3997-4004
16. #; #; ; ; ; *; How to handle the delayed or missed dose of rivaroxaban in patients with non-valvular atrial fibrillation: model-informed remedial dosing, Expert Review of Clinical Pharmacology, 2021, 14(9): 1153-1163
17. ; ; ; ; *; How important are MIC determination methods when targeting vancomycin levels in patients with Staphylococcus aureus infections? The Journal of Antimicrobial Chemotherapy,2021, 76(6): 1641-1643
18. ; ; ; *; Population Pharmacokinetics of Levetiracetam: A Systematic Review, Clinical Pharmacokinetics, 2021, 60(3): 305-318
19. *; ; ; ; ; ; ; ; ; Population pharmacokinetics of ivermectin for the treatment of scabies in Indigenous Australian children, PLoS Neglected Tropical Diseases, 2020, 14(12): e0008886
20. ; ; ; ; ; ; ; *; Disease progression model of 4T1 metastatic breast cancer. Journal of Pharmacokinetics and Pharmacodynamics, 2020, 47(1): 105-116
21. *; ; ; ; ; ; ; ; ; ; ; Model-based analysis on systemic availability of coadministered cannabinoids after controlled vaporised administration, Internal Medicine Journal,2019, 50(7): 846-853
22. #; #; ; ; ; *; Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients. Acta Pharmacologica Sinica, 2018, 39(2): 286-293
23. ; ; ; ; ; ; *; In silico drug absorption tract: An agent-based biomimetic model for human oral drug absorption, PloS One, 2018, 13(8): e0203361
24. #; #; ; ; ; ; ; *; *; Population pharmacokinetic analysis of tacrolimus in Chinese myasthenia gravis patients, Acta Pharmacologica Sinica, 2017, 38(8): 1195-1204
25. ; ; ; ; ; ; ; ; *; A Review of Food-Drug Interactions on Oral Drug Absorption, Drugs, 2017, 77(17): 1833-1855
26. ; ; ; ; ; ; ; ; *; Pharmacokinetic-Pharmacodynamic Modeling of the Anti-Tumor Effect of Sunitinib Combined with Dopamine in the Human Non-Small Cell Lung Cancer Xenograft, Pharmaceutical Research, 2017, 34(2): 408-418
27. #; #; ; ; ; *; *; Pharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in human breast cancer xenograft mice, Acta Pharmacologica Sinica, 2016, 37(6): 825-833
28. ; ; ; ; ; ; *; *; Imaging acidosis in tumors using a pH-activated near-infrared fluorescence probe,Chemical Communications,2012, 48(95): 11677-11679
29. Yile Chen; Xiao Zhu; Yingjia Yu*; Yi Cai; Yan Li; Gengli Duan; Comparison of infrared-assisted extraction and other techniques for analysis of indigo and indirubin in leaves of isatis indigotica fort, Journal of Liquid Chromatography & Related Technologies,2012, 35(3): 362-374
30. 季双敏; 朱校; 高柳村; 杨焕; 高晨燕; 靶介导的药物处置模型研究进展, 中国临床药理学与治疗学, 2018, 23(5): 481-487
31. 季双敏; 朱校*; 靶点介导的药物处置模型在单克隆抗体药物研发中应用的探讨, 中国临床药理学与治疗学, 2018, 23(3): 241-246
学术报告
1. 报告题目：定量药理学在儿科抗感染精准用药中的应用。会议名称：2023年中国药理学会临床药理专业委员会青年创新论坛，济南，中国
2. 报告题目：Use of Pharmacokinetic and Pharmacodynamic Analysis in Drug Discovery。会议名称：ASCEPT Annual Scientific Meeting，悉尼，澳大利亚
3. 报告题目：Deciphering the Complex DMPK Behavior of CNS Drug SIPI6398 Via Model-Based Approach。会议名称：2023 ISQP会议，上海，中国
4. 报告题目：转化PK/PD助力双特异性抗体的临床开发。会议名称：2023 DIA中国年会，苏州，中国
5. 报告题目：模型引导的新药研发。会议名称：2023中国医学前沿大会，北京，中国
6. 报告题目：时间-事件分析在婴幼儿葡萄球菌感染治疗靶标确定中的应用。会议名称：2022首届西部定量药理青年论坛，成都，中国
7. 报告题目：Last-mile delivery: a reference plot to help non-pharmacometrician interpret population pharmacokinetics results。会议名称：ISQP 2021, 北京，中国
8. 报告题目：Determination of the pharmacodynamics of vancomycin in young infants via time-to-event analysis。会议名称：PAGANZ Virtual Meeting 2021, 悉尼, 澳大利亚
9. 报告题目：An evaluation of timed snapshot signalling bias analyses for nonequilibrium systems。会议名称：ASCEPT-PAGANZ 2019 Joint Scientific Meeting, 皇后镇, 新西兰
10. 报告题目：A cohesive model framework of receptor pharmacology: beyond the Emax model。会议名称：Population Approach Group in Europe (PAGE) 2019, 斯德哥尔摩, 瑞典
11. 报告题目：Evaluation of the fingerprint profiles of the cannabinoid-1 receptor signalling via a kinetic modelling approach。PAGANZ Meeting 2019, 奥克兰, 新西兰
12. 报告题目：A kinetic model for describing signalling profiles of the cannabinoid-1 receptor. 会议名称：ASCEPT NZ Meeting 2018, 皇后镇, 新西兰
13. 报告题目：Kinetic modelling of ligand mediated internalisation。会议名称：PAGANZ Meeting 2018, 墨尔本, 澳大利亚
14. 报告题目：An intact model framework for quantifying functional selectivity。会议名称： ASCEPT NZ Meeting 2017, 皇后镇, 新西兰
15. 报告题目：Identifiability analysis of empirical models used for quantifying “biased” ligands。会议名称：PAGANZ Meeting 2017, 阿德莱德, 澳大利亚
